Cystic Fibrosis (CF) is characterized by an aggressive inflammatory response. One important marker of CF lung disease, the pleiotropic cytokine TGF-beta, is negatively regulated by E3-ubiquitin ligases, which have been found to be dysregulated in previous studies of F508del-CFTR-related gene expression. To understand the role of E3-ubiquitin ligases in CF, we studied the effects of: 1. F508del mutation and 2. exposure to TGF-beta and TNF-alpha cytokines on mRNA and protein expression of the E3-ubiquitin ligases SMURF1, SMURF2 and NEDD4L in polarized CF bronchial epithelial cell models. Using real-time quantitative PCR, we demonstrated that the F508del mutation is not sufficient to induce significant differential mRNA expression of E3-ubiquitin ligases. However, the F508del-CFTR genotype altered the responsiveness of E3ubiquitin ligases to both inflammatory cytokines. Our results showed that both TGF-beta and TNF-alpha increased the expression of SMURF2 mRNA in F508del-CFTR CFBE cells, suggesting an up-regulation of this E3-ubiquitin ligase under inflammatory status. In addition, this increased expression was consistent with an observed decrease in SMAD2 and SMAD3 mRNA expression. These results suggest that increased expression of E3-ubiquitin ligases in CF under inflammation could be partly responsible for the increased pro-inflammatory mediators that characterize CF disease, via an inhibition of the Smad-dependent anti-inflammatory effects of TGF-beta. Our preliminary data enlighten the potential implications of differential expression of enzymes involved in ubiquitination on modulation of CF inflammatory responses.
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162 Serum amyloid A as a useful serum marker of lung inflammation in cystic fibrosis F. Cresta 1 , A. Naselli 1 , F. Favilli 1 , R. Casciaro 1 , A. De Alessandri 1 , A. Pistorio 2 , L. Minicucci 1 . 1 IRCCS G. Gaslini, Cystic Fibrosis Centre, Genoa, Italy; 2 IRCCS G. Gaslini, Scientific Direction, Epidemiology Service, Genoa, Italy Anti-inflammatories are an attractive therapeutic target in CF with a proven ability to slow down lung disease. Up to now, a serum biomarker able to define inflammation baseline state and to determine therapy efficacy, is not available. Serum amyloid A (SAA) is an acute-phase protein, whose serum concentration represents a useful inflammatory marker, particularly in rheumatic diseases. We decided to compare SAA values with CRP values, that are strongly related with acute infective exacerbations, and clinical parameters, useful to define baseline lung condition. We tested SAA (normal value: <6.4 mg/l) in 147 serum samples from 107 CF patients, followed by Genoa CF Centre in 2012. We divided SAA results in 5 groups and we collected for each patient age, average annual FEV1%, P. aeruginosa colonization and CRP value at the time of every SAA collection (Table 1) . P.a. positivity is highly related with SAA values (median value in P.a. positive 50.1 mg/l, median value in P.a. negative 5.5 mg/l: p < 0.0001). No correlation was observed between SAA values and age (r s = 0.29). A strong correlation was observed between SAA and CRP values (n = 147; r s = 0.77) and a moderate inverse correlation emerged between SAA and FEV 1 % (n = 133; r s = −0.58). In conclusion SAA, in CF, can be useful to define, as CRP, acute inflammatory events, but also to characterize lung inflammatory baseline condition. Objectives: SLPI and elafin are members of the WAP Four-Disulphide-Core (WFDC) family of proteins and have multiple contributions to innate immunity including inhibition of neutrophil serine proteases and inhibition of the inflammatory response to LPS. The aims of this research were to explore potential activities of WAP2, a previously uncharacterised WFDC protein expressed in the lung. Methods: Recombinant expression and purification of WAP2 were optimised in E. coli. Cathepsin G and elastase activity assays were used to test anti-protease activity of rWAP2. To investigate anti-inflammatory activity, THP-1 monocytic cells were given LPS alone or rWAP2 in combination with LPS. Cytokine levels in cellfree supernatants were subsequently analysed by ELISA. To test if WAP2 could become cross-linked to extracellular matrix proteins, rWAP2 was incubated with fibronectin +/− transglutaminase, and then assessed by SDS-PAGE and Western blotting. BALF samples from CF patients were examined for the presence of endogenous WAP2 via Western blot. Conclusion: Recombinant WAP2 inhibited cathepsin G but not elastase activity.
Monocytic cells pre-treated with rWAP2 before LPS stimulation showed significantly lower levels of IL-8 and MCP-1 production compared to cells given LPS alone. Recombinant WAP2 was conjugated to fibronectin in a transglutaminasemediated reaction and retained anti-protease activity. WAP2 was detected at variable levels in BALF from CF patients. Together these results suggest a role for this lesser known WFDC protein in the regulation of inflammation; therefore further investigation is warranted to determine its merit as a possible therapeutic agent.
